BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 369 filers reported holding BIO-TECHNE CORP in Q4 2019. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,830,811 | -17.1% | 26,896 | -0.6% | 0.00% | -33.3% |
| Q2 2023 | $2,207,683 | +3.0% | 27,045 | -6.4% | 0.00% | 0.0% |
| Q1 2023 | $2,143,275 | +88.7% | 28,889 | +110.9% | 0.00% | +50.0% |
| Q4 2022 | $1,135,539 | +35.5% | 13,701 | +364.4% | 0.00% | +100.0% |
| Q3 2022 | $838,000 | +161.9% | 2,950 | +219.6% | 0.00% | 0.0% |
| Q2 2022 | $320,000 | -6.7% | 923 | +16.7% | 0.00% | 0.0% |
| Q1 2022 | $343,000 | -5.5% | 791 | +12.7% | 0.00% | 0.0% |
| Q4 2021 | $363,000 | +17.1% | 702 | +9.7% | 0.00% | 0.0% |
| Q3 2021 | $310,000 | +8.8% | 640 | +1.3% | 0.00% | 0.0% |
| Q2 2021 | $285,000 | -32.1% | 632 | -42.5% | 0.00% | 0.0% |
| Q1 2021 | $420,000 | +29.6% | 1,099 | +7.7% | 0.00% | 0.0% |
| Q4 2020 | $324,000 | -9.7% | 1,020 | -29.6% | 0.00% | 0.0% |
| Q3 2020 | $359,000 | -19.3% | 1,449 | -14.0% | 0.00% | 0.0% |
| Q2 2020 | $445,000 | +34.0% | 1,684 | -3.9% | 0.00% | 0.0% |
| Q1 2020 | $332,000 | -15.1% | 1,753 | -1.6% | 0.00% | 0.0% |
| Q4 2019 | $391,000 | +10.5% | 1,782 | -1.4% | 0.00% | 0.0% |
| Q3 2019 | $354,000 | -4.8% | 1,808 | +1.3% | 0.00% | 0.0% |
| Q2 2019 | $372,000 | +5.1% | 1,785 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $354,000 | +42.7% | 1,785 | +4.1% | 0.00% | 0.0% |
| Q4 2018 | $248,000 | -34.4% | 1,714 | -7.5% | 0.00% | 0.0% |
| Q3 2018 | $378,000 | +42.6% | 1,853 | +3.6% | 0.00% | 0.0% |
| Q2 2018 | $265,000 | -1.9% | 1,789 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $270,000 | +94.2% | 1,789 | +51.7% | 0.00% | 0.0% |
| Q2 2017 | $139,000 | +3.7% | 1,179 | -10.3% | 0.00% | 0.0% |
| Q1 2017 | $134,000 | -20.2% | 1,315 | -19.3% | 0.00% | 0.0% |
| Q4 2016 | $168,000 | -2.3% | 1,629 | +4.0% | 0.00% | 0.0% |
| Q3 2016 | $172,000 | -0.6% | 1,567 | +2.4% | 0.00% | 0.0% |
| Q2 2016 | $173,000 | +19.3% | 1,530 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $145,000 | 0.0% | 1,530 | -5.0% | 0.00% | 0.0% |
| Q4 2015 | $145,000 | -3.3% | 1,610 | -0.9% | 0.00% | 0.0% |
| Q3 2015 | $150,000 | -6.8% | 1,624 | +0.9% | 0.00% | -50.0% |
| Q1 2015 | $161,000 | -5.3% | 1,610 | -12.5% | 0.00% | 0.0% |
| Q4 2014 | $170,000 | – | 1,839 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |